INTENSITY THERAPEUTICS, INC. (INTS)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$10.2M
Cash & Equivalents
$1.8M
Quarterly Burn Rate
17 mo
Est. Cash Runway
$13M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06263231 A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Ti... PHASE3 Active Not Recruiting 333

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for INTS.

SEC EDGAR Filings

All SEC filings for INTENSITY THERAPEUTICS, INC. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.